Anti-CTLA4 antibody-TGF-βRII targeted/immunomodulatory fusion proteins
US9758582B2 · kind B2 · utility
5Cited by
1References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 3, 2016 |
| Grant date | Sep 12, 2017 |
| Priority date | — |
| Expiry date | May 3, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2500/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.